Effectiveness of Pre-Exposure Prophylaxis To Prevent HIV Infection: Findings of a Systematic Review

This interactive visualization displays pooled estimates of meta-analysis results and individual study estimates of trials of HIV pre-exposure prophylaxis (PrEP) in people without HIV infection at high risk of becoming infected. The outcomes shown are HIV infection, mortality, and various other harms. The data are organized by the following study drugs and comparisons: oral PrEP (tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) or tenofovir disoproxil fumarate (TDF)) vs. placebo, dapivirine vs. placebo, cabotegravir vs. tenofovir disoproxil fumarate plus emtricitabine (TDF-FTC), and tenofovir alafenamide plus emtricitabine (TAF-FTC) vs. TDF-FTC. Meta-analysis was not conducted for all drugs, comparisons, and outcomes; therefore only individual study data are sometimes displayed. There are two dashboards, one showing benefits and the other showing harms. Select the tabs or radio buttons to choose which data to show. Hover over the elements in the data for additional details.

Source: Chou R, Spencer H, Bougatsos C, Blazina I, Ahmed A, Selph S. Pre-Exposure Prophylaxis for the Prevention of HIV Infection: A Systematic Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 228. AHRQ Publication No. 22-05300-EF-1. Rockville, MD: Agency for Healthcare Research and Quality. 2023.